2nd Workshop: The new ParadIgM – IgM from bench to clinic


  Programme as pdf for download
  TUESDAY, APRIL 23, 2013 
09:00  Registration
09:30 Welcome and Opening
09:45 Keynote Lecture
IgM - the past and the present
N.H. Teng, Stanford University, School of Medicine, CA/USA
10:15  Competitive binding of GRP78 and LDL to the anti-cancer monoclonal IgM PAT-SM6
Z. Rosenes, Y.F. Mok, T.D. Mulhern, D.M. Hatters, G.J. Howlett, University of Melbourne/AUS
10:45 Short presentation: A method for in vitro generation of diagnostic and therapeutically antibodies
K. Müller-Zahm, S. Thiele, D. Paul, P. Miethe, FZMB GmbH, Bad Langensalza/D
11:00 Coffee break



Production of different IgM glycoforms in Nicotiana benthamiana
A. Loos, C. Gruber, University of Natural Resources and Life Sciences, Vienna/A;
F. Hensel, Patrys GmbH, Würzburg/D; F. Altmann, H. Steinkellner, University of Natural Resources and Life Sciences, Vienna/A


IgG to IgM class switch: modification of protein properties by antibody engineering
A. Mader
, V. Chromikova, R. Kunert, University of Natural Resources and Life Sciences, Vienna/A


Generation of antibodies targeting cell surface antigens on ovarian cancer cells
A. Choo, L. Luk, H.L. Tan, Bioprocessing Technology Institute, Singapore/SGP


Lunch, followed by coffee break and exhibition



14:00 A rapid one-step hydroxyapatite method to obtain highly purified monoclonal IgM for research use
X. He, Bio-Rad Laboratories, Hercules, CA/USA; T. Gan, S. Latiff, W. Lau, P. Gagnon, Bioprocessing Technology Institute, Singapore/SGP


The preparative purification and analysis of immunoglobulin M utilizing ion exchange and affinity chromatography with a novel affinity ligand immobilized on a robust high throughput resin
C. Gebski, P. Lynch, Life Technologies, Bedford, MA/USA
15:00 HPLC method for quantitative determination of CHO-cell recombinant monoclonal IgM antibody
M. Zorz, S. Peljhan, M. Barut, A. Strancar, BIA Separations d.o.o., Ajdovscina/SLO;
R. Weik, H. Katinger, Polymun Scientific GmbH, Klosterneuburg/A

Coffee break

16:00 Characterization and evaluation of potential IgM capture matrices
J. Schreffler, E. Wiltsie, Morphotek, Inc., Exton, PA/USA


Exclusively monolithic purification of clinical grade IgM monoclonal antibodies
P. Gagnon, H.T. Gan, J . Lee, S.M. Abdul Latiff, C. Chuah, Bioprocessing Technology Institute, Singapore/SGP

17:00 - 17:30

Stability of IgMs at low pH used during purification and during storage
M. Müller
, University of Vienna/A and, Bioprocessing Technology Institute, Singapore/SGP; M. Loh, Bioprocessing Technology Institute, Singapore/SGP;
A. Jungbauer, University of Natural Resources and Applied Life Sciences/A;
M. Bardor, P. Gagnon, Bioprocessing Technology Institute, Singapore/SGP


Get-Together - to be announced onsite


09:00 Efficient inactivation of small non-enveloped viruses in IgM processes
A. Meyer, Sartorius Stedim Biotech GmbH, Göttingen/D

Development of a second-generation downstream process for an IgM therapeutic
T. O'Neill, G. Bremer, V. Castens, X. Yang, M. Ultee, Laureate Biopharmaceutical Services, Inc., Princeton, NJ/USA

10:00 Improving robustness and safety of a downstream process for IgM
J. Abildskov, S. Bergmann, CMC Biologics A/S, Copenhagen/DK
10:30 Coffee break

Manufacture of recombinant IgM-antibodies - a case study
K. Fauland, R. Weik, Polymun Scientific GmbH, Klosterneuburg/A; M. Barut,
S. Peljhan, A. Strancar, M. Zorz, BIA Separations d.o.o., Ajdovscina/SLO; R. Kunert, K. Vorauer-Uhl, University of Natural Resources and Applied Life Sciences/A;
H. Katinger, Polymun Scientific GmbH, Klosterneuburg and University of Natural Resources and Applied Life Sciences/A


Analytical methods to support IgM development and manufacturing
S.D. Jones, BioProcess Technology Consultants, Inc., Woburn, MA/USA

 12:00 Special lecture
IP protection strategies - from ideas to patents

R. Seifert, Patentquadrat, Martinsried/D

The birth pangs ofmonoclonal antibody therapeutics
L. Marks, King's College London/UK 


Lunch, followed by coffee break and exhibition


Preclinical investigations of natural regulatory antibodies to apoptotic cells
G.J . Silverman, C. Grönwall, NYU School of Medicine, New York/USA


10 years follow-up of a prospective trial for targeted therapy of gastric cancer with the human monoclonal antibody PAT-SC1
F. Hensel
, Patrys GmbH, Würzburg/D; B. I llert, Sana Kliniken Ostholstein, Eutin/D;
W. Timmermann, Allgemeines Krankenhaus - Klinik für Allgemein- und Viszeralchirurgie, Hagen/D; A. Rosenwald, S. Brändlein, University Hospital, University of Würzburg/D

15:00 Does a "thiol shield" protect tumors from natural IgM antibody, and, if so, how can it be suppressed?
P. Jones, John Wayne Cancer Institute, Los Angeles, CA/USA
15:30 Coffee break
16:00 Natural human autoreactive IgMs as therapeutics for neurologic disease: from discovery, to recombinant, to trial
A.E. Warrington, M. Rodriguez, Mayo Clinic, Rochester, MN/USA
16:30 Pre-clinical and early clinical development of human IgM antibody PAT-SM6
V. Dubljevic, Patrys Ltd., Melbourne/AUS; L. Rasche, Universitätsklinikum Würzburg/D; S. Braendlein, University Hospital, University of Würzburg/D; F. Hensel, Patrys GmbH, Würzburg/D

Harnessing therapeutic potential of natural IgM: Is it about time?
S.V. Kaveri, INSERM, Paris/F

17:30 End of the workshop


Jetzt Mitglied werden